Korro Bio (KRRO) EBITDA (2018 - 2026)

Korro Bio (KRRO) has reported EBITDA for 9 consecutive years, with -$20.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA rose 26.07% year-over-year to -$20.1 million; the trailing twelve-month figure through Jun 2026 stood at -$110.2 million (down 11.8% YoY), and the FY2025 full-year result was -$121.9 million, down 32.58% from the prior year.
• EBITDA improved to -$20.1 million in Q2 2026 per KRRO's latest filing, from -$20.4 million in the prior quarter.
• Across five years, EBITDA topped out at $5.8 million in Q4 2022 and bottomed at -$50.4 million in Q4 2025.
• Historically, EBITDA has averaged -$22.1 million across 5 years, with a median of -$21.4 million in 2022.
• The sharpest annual moves came in 2022 and 2023: EBITDA soared 127.19% in 2022, then slumped 563.03% in 2023.
• Over 5 years, EBITDA stood at $5.8 million in 2022, then plunged by 563.03% to -$26.9 million in 2023, then grew by 14.33% to -$23.0 million in 2024, then sank by 118.73% to -$50.4 million in 2025, then jumped by 60.1% to -$20.1 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$20.1 million, -$20.4 million, and -$50.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.